Generalized Holographic Quantum Criticality at Finite Density

We show that the near-extremal solutions of Einstein-Maxwell-Dilaton theories, studied in ArXiv:1005.4690, provide IR quantum critical geometries, by embedding classes of them in higher-dimensional AdS and Lifshitz solutions. This explains the scaling of their thermodynamic functions and their IR transport coefficients, the nature of their spectra, the Gubser bound, and regulates their singularities. We propose that these are the most general quantum critical IR asymptotics at finite density of EMD theories.Comment: v4: Corrected the scaling equation for the conductivity in section 9.

Effective Holographic Theories for low-temperature condensed matter systems

The IR dynamics of effective holographic theories capturing the interplay between charge density and the leading relevant scalar operator at strong coupling are analyzed. Such theories are parameterized by two real exponents $(\gamma,\delta)$ that control the IR dynamics. By studying the thermodynamics, spectra and conductivities of several classes of charged dilatonic black hole solutions that include the charge density back reaction fully, the landscape of such theories in view of condensed matter applications is characterized. Several regions of the $(\gamma,\delta)$ plane can be excluded as the extremal solutions have unacceptable singularities. The classical solutions have generically zero entropy at zero temperature, except when $\gamma=\delta$ where the entropy at extremality is finite. The general scaling of DC resistivity with temperature at low temperature, and AC conductivity at low frequency and temperature across the whole $(\gamma,\delta)$ plane, is found. There is a codimension-one region where the DC resistivity is linear in the temperature. For massive carriers, it is shown that when the scalar operator is not the dilaton, the DC resistivity scales as the heat capacity (and entropy) for planar (3d) systems. Regions are identified where the theory at finite density is a Mott-like insulator at T=0. We also find that at low enough temperatures the entropy due to the charge carriers is generically larger than at zero charge density.Comment: (v3): Added discussion on the UV completion of the solutions, and on extremal spectra in the charged case. Expanded discusion on insulating extremal solutions. Many other refinements and corrections. 126 pages. 48 figure

Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System

<p>Abstract</p> <p>Background</p> <p>Peroxisome proliferator-activated receptors (PPARs) have emerged as important drug targets for diabetes. Drugs that activate PPARγ, such as the thiazolidinediones (TZDs), are widely used for treatment of Type 2 diabetes mellitus. PPARγ signaling could also play an anti-neoplastic role in several <it>in vitro </it>models, although conflicting results are reported from <it>in vivo </it>models. The effects of TZDs on cancer risk in humans needs to be resolved as these drugs are prescribed for long periods of time in patients with diabetes.</p> <p>Methods</p> <p>A total of 1003 subjects in community practice settings were interviewed at home at the time of enrolment into the Vermont Diabetes Information System, a clinical decision support program. Patients self-reported their personal and clinical characteristics, including any history of malignancy. Laboratory data were obtained directly from the clinical laboratory and current medications were obtained by direct observation of medication containers. We performed a cross-sectional analysis of the interviewed subjects to assess a possible association between cancer diagnosis and the use of TZDs.</p> <p>Results</p> <p>In a multivariate logistic regression model, a diagnosis of cancer was significantly associated with TZD use, even after correcting for potential confounders including other oral anti-diabetic agents (sulfonylureas and biguanides), age, glycosylated hemoglobin A1C, body mass index, cigarette smoking, high comorbidity, and number of prescription medications (odds ratio = 1.59, <it>P </it>= 0.04). This association was particularly strong among patients using rosiglitazone (OR = 1.89, <it>P </it>= 0.02), and among women (OR = 2.07, <it>P </it>= 0.01).</p> <p>Conclusion</p> <p>These data suggest an association between TZD use and cancer in patients with diabetes. Further studies are required to determine if this association is causal.</p

A Chiral Magnetic Effect from AdS/CFT with Flavor

For (3+1)-dimensional fermions, a net axial charge and external magnetic field can lead to a current parallel to the magnetic field. This is the chiral magnetic effect. We use gauge-gravity duality to study the chiral magnetic effect in large-Nc, strongly-coupled N=4 supersymmetric SU(Nc) Yang-Mills theory coupled to a number Nf << Nc of N=2 hypermultiplets in the Nc representation of SU(Nc), i.e. flavor fields. Specifically, we introduce an external magnetic field and a time-dependent phase for the mass of the flavor fields, which is equivalent to an axial chemical potential for the flavor fermions, and we compute holographically the resulting chiral magnetic current. For massless flavors we find that the current takes the value determined by the axial anomaly. For massive flavors the current appears only in the presence of a condensate of pseudo-scalar mesons, and has a smaller value than for massless flavors, dropping to zero for sufficiently large mass or magnetic field. The axial symmetry in our system is part of the R-symmetry, and the states we study involve a net flow of axial charge to the adjoint sector from an external source coupled to the flavors. We compute the time rate of change of axial charge and of energy both in field theory and from holography, with perfect agreement. In contrast to previous holographic models of the chiral magnetic effect, in our system the vector current is conserved and gauge-invariant without any special counterterms.Comment: 54 pages, 18 eps files in 6 figure

State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS)

PCOS, a heterogeneous disorder characterized by cystic ovarian morphology, androgen excess, and/or irregular periods, emerges during or shortly after puberty. Peri- and post-pubertal obesity, insulin resistance and consequent hyperinsulinemia are highly prevalent co-morbidities of PCOS and promote an ongoing state of excess androgen. Given the relationship of insulin to androgen excess, reduction of insulin secretion and/or improvement of its action at target tissues offer the possibility of improving the physical stigmata of androgen excess by correction of the reproductive dysfunction and preventing metabolic derangements from becoming entrenched. While lifestyle changes that concentrate on behavioral, dietary and exercise regimens should be considered as first line therapy for weight reduction and normalization of insulin levels in adolescents with PCOS, several therapeutic options are available and in wide use, including oral contraceptives, metformin, thiazolidenediones and spironolactone. Overwhelmingly, the data on the safety and efficacy of these medications derive from the adult PCOS literature. Despite the paucity of randomized control trials to adequately evaluate these modalities in adolescents, their use, particularly that of metformin, has gained popularity in the pediatric endocrine community. In this article, we present an overview of the use of insulin sensitizing medications in PCOS and review both the adult and (where available) adolescent literature, focusing specifically on the use of metformin in both mono- and combination therapy